← back to search

Xiao Ding

Jiangnan University · CN
Area of research
Molecular Biology · Hepatology
Research interest
Research interests include Hepatitis C virus research, CRISPR and Genetic Engineering, Gut microbiota and health, and Clostridium difficile and Clostridium perfringens research.
h-index
44
citations
11,140
works
193
NIH funding
primary concept
email

Recent publications

Unveiling the power of Treg.Sig: a novel machine-learning derived signature for predicting ICI response in melanoma
Frontiers in Immunology 2025cited by 0position: middledoi
Influenza virus reassortment patterns exhibit preference and continuity while uncovering cross-species transmission events.
2025cited by 0position: contributordoi
Diversity, Complexity, and Challenges of Viral Infectious Disease Data in the Big Data Era: A Comprehensive Review.
2025cited by 0position: contributordoi
Evaluating the performance of the PREDAC method in flu vaccine recommendations over the past decade (2013–2023)
Virologica Sinica 2025cited by 0position: contributordoi
Deep learning predicts potential reassortments of avian H5N1 with human influenza viruses.
2025cited by 0position: contributordoi
Genome-wide identification of characteristic nucleotide fragments for surveillance and subtype typing of influenza A viruses
Decoding Infection and Transmission 2025cited by 0position: contributordoi
Transmission restriction and genomic evolution co-shape the genetic diversity patterns of influenza A virus.
2024cited by 5position: contributordoi
The spatiotemporal analysis of SARS-CoV-2 transmission in China since the termination of the dynamic zero-COVID policy.
2024cited by 3position: contributordoi
Development of PREDAC-H1pdm to model the antigenic evolution of influenza A/(H1N1) pdm09 viruses.
2023cited by 4position: contributordoi
Mapping Genetic Events of SARS-CoV-2 Variants.
2022cited by 5position: contributordoi
Origin and Reversion of Omicron Core Mutations in the Evolution of SARS-CoV-2 Genomes.
2022cited by 2position: contributordoi
One year of SARS-CoV-2 evolution
Cell Host & Microbe 2021cited by 80position: middledoi
Herbicide Resistance: Another Hot Agronomic Trait for Plant Genome Editing
Plants 2021cited by 58position: middledoi
One year of SARS-CoV-2 evolution.
2021cited by 58position: contributordoi
Co-mutation modules capture the evolution and transmission patterns of SARS-CoV-2
Briefings in Bioinformatics 2021cited by 30position: middledoi
Co-mutation modules capture the evolution and transmission patterns of SARS-CoV-2.
2021cited by 17position: contributordoi
Progress and Challenge in Computational Identification of Influenza Virus Reassortment.
2021cited by 5position: contributordoi
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Cell Host & Microbe 2020cited by 2,532position: middledoi
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China.
2020cited by 1,469position: contributordoi
FluReassort: a database for the study of genomic reassortments among influenza viruses.
2020cited by 9position: contributordoi
Cluster-Transition Determining Sites Underlying the Antigenic Evolution of Seasonal Influenza Viruses.
2019cited by 11position: contributordoi
Protective effect of DHEA on hydrogen peroxide-induced oxidative damage and apoptosis in primary rat Leydig cells
Oncotarget 2017cited by 20position: firstdoi
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Gastroenterology 2016cited by 211position: middledoi
Dehydroepiandrosterone inhibits cell proliferation and improves viability by regulating S phase and mitochondrial permeability in primary rat Leydig cells
Molecular Medicine Reports 2016cited by 19position: middledoi
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
Hepatology 2015cited by 256position: middledoi
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Hepatology 2015cited by 90position: middledoi
Dehydroepiandrosterone ameliorates H2O2-induced Leydig cells oxidation damage and apoptosis through inhibition of ROS production and activation of PI3K/Akt pathways
The International Journal of Biochemistry & Cell Biology 2015cited by 45position: firstdoi
Dehydroepiandrosterone-Regulated Testosterone Biosynthesis via Activation of the ERK1/2 Signaling Pathway in Primary Rat Leydig Cells
Cellular Physiology and Biochemistry 2015cited by 16position: middledoi
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
New England Journal of Medicine 2014cited by 1,702position: middledoi
Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
Hepatology 2014cited by 196position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John G. McHutchison · Gilead Sciences (United States)5 papers (2014–2016)Phillip S. Pang · Gilead Sciences (United States)4 papers (2014–2016)Haitian Ma · Nanjing Agricultural University4 papers (2015–2017)Nezam H. Afdhal · Harvard University4 papers (2014–2016)Alessandra Mangia · NIHR Birmingham Biomedical Research Centre3 papers (2014–2015)Patrick Marcellin · Assistance Publique – Hôpitaux de Paris3 papers (2014–2015)K. Rajender Reddy · Fred Hutch Cancer Center3 papers (2014–2015)William T. Symonds · Gilead Sciences (United States)3 papers (2014–2015)Mark Sulkowski · Johns Hopkins Bayview Medical Center3 papers (2014–2015)Eric Lawitz · Indiana University – Purdue University Indianapolis3 papers (2014–2016)Edward Gane · New Zealand Christians in Science3 papers (2014–2016)Taijiao Jiang · Guangzhou Medical University3 papers (2020–2021)Jenny C. Yang · Gilead Sciences (United States)3 papers (2014–2015) · 3 papers (2020–2025)Hadas Dvory‐Sobol · Medizinische Hochschule Hannover2 papers (2015–2016)Paul Y. Kwo · Palo Alto University2 papers (2014–2015)Shu-Min Chuang · Gilead Sciences (United States)2 papers (2014–2016)Julie Ma · Southwestern Medical Center2 papers (2014–2016)Stefan Zeuzem · Heidelberg University2 papers (2015–2015)Aiping Wu · Wannan Medical College2 papers (2020–2021)